KR930019829A - 엡스타인 바르 비루스(Epstein Barr Virus)와 관련된 펩티드 및 핵산 서열 - Google Patents

엡스타인 바르 비루스(Epstein Barr Virus)와 관련된 펩티드 및 핵산 서열 Download PDF

Info

Publication number
KR930019829A
KR930019829A KR1019930003940A KR930003940A KR930019829A KR 930019829 A KR930019829 A KR 930019829A KR 1019930003940 A KR1019930003940 A KR 1019930003940A KR 930003940 A KR930003940 A KR 930003940A KR 930019829 A KR930019829 A KR 930019829A
Authority
KR
South Korea
Prior art keywords
acid sequence
epstein
antibody
nucleic acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019930003940A
Other languages
English (en)
Other versions
KR100291247B1 (ko
Inventor
마이클 미델도르프 재프
Original Assignee
에프. 쥐. 엠. 헤르만스, 에이. 쥐. 제이. 베르미어렌
악조 엔. 브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 쥐. 엠. 헤르만스, 에이. 쥐. 제이. 베르미어렌, 악조 엔. 브이. filed Critical 에프. 쥐. 엠. 헤르만스, 에이. 쥐. 제이. 베르미어렌
Publication of KR930019829A publication Critical patent/KR930019829A/ko
Application granted granted Critical
Publication of KR100291247B1 publication Critical patent/KR100291247B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 EBA 오픈 리딩 프레임(open reading frame)DLS BFRF 3과 BdRF1 내에서 각각 암호된 VCA-p18이나 VCA-p40 단백질을 적어도 일부분 또는 그것의 작용성 변이체를 포함하고 있고, 엡스타인-바르 비루스(Epstein Barr virus)에 대한 항체와 면역화학적으로 반응적인 펩티드에 관한 것이다. 또한 본 발명은 이들 펩티드를 암호하는 핵산 서열, 이들 펩티드에 대하여 생성된 단일클론 항체, 이 단일클론 항체를 생성할 수 있는 세포주 및 항-유전인자형 항체에 관한 것이다.
본 발명은 또한 본 발명의 핵산 서열을 포함하는 제조합 벡터의 분자 및 이 벡터 분사로 형질전환되거나 형질감염된 숙주세포에 관한 것이다. 본 발명은 또한 EBV 또는 항-EBV 항체를 검측하기 위한 방법 및 면역학적 시약 그리고 엡스타인 바르 비루스 핵산을 증폭시키고 검측하는 방법에 관한 것이다.

Description

엡스타인 바르 비루스(Epstein Barr Virus)와 관련된 펩티드 및 핵산 서열.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 : VCA-p40 및 VCA-p18 단백질을 암호화하는 EBV-암호화된 유전자를 동정하기 위한 시도의 요약.
제2도 : a) EA 및 VCA의 발현을 위해 유도된 비루스-생산 세포주 HH514의 핵의 항원 추출물의 웨스턴 블로트, b) BFRF3-β-갈락토시다제 융합 단백질을 발현시키는 이. 콜리의 전체 세포 분해질의 웨스턴 블로드, c) BdRF1-β-갈락토시다제 융합 단백질을 발현시키는 이. 콜리의 전체 세포 분해질의 웨스턴 블로드. d) β-갈락토시다제만을 발현시키는 이. 콜리의 전체 세포 분해질의 웨스턴 블로트.

Claims (25)

  1. EBV 오픈 리딩 프레임(open reading frame)DLS BFRF 3과 BdRF1 내에서 각각 암호된 VCA-p18이나 VCA-p40 단백질을 적어도 일부분 또는 그것의 작용성 변이체를 포함하고 있고, 엡스타인-바르 비루스(Epstein Barr virus)에 대한 항체와 면역화학적으로 반응적인 펩티드.
  2. 제1항에 있어서, 서열 동정 번호 2에 나타낸 아미노산 서열의 적어도 일부분 또는 그것의 작용성 변이체를 포함하고 있는 펩티드.
  3. 제1항에 있어서, 서열 동정 번호 4에 나타낸 아미노산 서열의 적어도 일부분 또는 그것의 작용성 변이체를 포함하고 있는 펩티드.
  4. 제2항에 있어서, 서열 동정 번호 5와 6에 나타낸 아미노산 서열 중에서 선책된 아미노산 서열을 적어도 하나 포함하는 펩티드.
  5. 제4항에 있어서, 서열 동정 번호 6에 나타낸 아미노산 서열에 연결된 서열 동정 번호 5에 나타낸 아미노산 서열을 포함하는 펩티드.
  6. 제1항 내지 제5항 중 어느 한 항의 펩티드를 암호하는 핵산 서열.
  7. 서열 동정 번호 1에 나타낸 핵산 서열을 적어도 일부분 포함하는 핵산 서열.
  8. 서열 동정 번호 3에 나타낸 핵산 서열을 적어도 일부분 포함하는 핵산 서열.
  9. 제6항 내지 제8항 중 어느 한 항의 핵산 서열을 포함하는 재조합 벡터분자.
  10. 제9항의 재조합 벡터 분자로 형질전환되거나 형질감염된 숙주세포.
  11. 제1항 내지 제5항 중 어느 한 항의 펩티드에 대하여 생성된 항체.
  12. 제11항에 있어서, 상기 항체는 단일 클론 항체인 것을 특징으로 하는 항체.
  13. 유럽 동물 세포 배양 수집소(ECACC, 영국 포톤 다운에 소재)에 기탁 번호 제93020413호 및 제 93020412호로 각각 기탁되어 있는 래트-마우스 하이브리도마 세포주가 생성하는 단일클론 항체 EBV.OT15E 또는 EBV.OT15Ⅰ로서, VCA-p18과 동일한 반응성을 가진 단일클론 항체.
  14. 유럽 동물 세포 배양 수집소(ECACC, 영국 포톤 다운에 소재)에 기탁 번호 제93020414호로 기탁되어 있는 마우스-마우스 하이브리도마 세포주가 생성하는 단일 클론 항체 EBV.OT41A로서, VCA-p40과 동일한 반응성을 가진 단일클론 항체.
  15. 제13항이나 제14항의 단일클론 항체를 생성할 수 있는 영구적인 세포주.
  16. 제15항에 있어서, 유럽 동물 세포 배양 수집소(ECACC, 영국 포톤 다운에 소재)에 기탁 번호 제93020413호, 제 93020412호 또는 제93020414호로 기탁되어 있는 영 구적인 세포주.
  17. 제11항의 항체와 반응적인 항-유전인자형 항체.
  18. 제11항 내지 제5항 중 어느 한 항의 펩티드(들)을 하나 이상 포함하는 면역화학 시약.
  19. 제11항 내지 제14항 중 어느 한 항의 항체들을 하나 이상 포함하는 면역화학 시약.
  20. 제11항 내지 제14항 중 어느 한 항의 항체를 샘플과 접촉시킨 후 형성된 면역 복합체의 상기 샘플 중의 엡스타인-바르 비루스 존재의 척도로서 검측하는 것을 특징으로 하는 샘플내에 엡스타인-바르 비루스를 검측하는 방법.
  21. 제14항의 면역화학 시약을 샘플과 접촉시킨 후 그 샘플내의 펩티드와 항체 사이에 형성된 면역 복합체의 존재를 상기 샘플 중의 엡스타인-바르 비루스에 대한 항체 존재이 척도로서 검측하는 것을 특징으로 하는 샘플내에 엡스타인-바르 비루스에 대하여 생성되는 항체의 검측 방법.
  22. 제1항 내지 제5항 중 어느 한 항의 하나 이상의 펩티드를 샘플 및 엡스타인 바르 비루스에 대하여 생성된 항체와 접촉시킨 후, 형성된 면역 복합체의 존재를 검측하고 이로부터 상기 샘플내의 엡스타인 바르 비루스의 존재가 층정됨을 특징으로 하는 상기 샘플내에 엡스타인-바르 비루스를 검측하는 방법.
  23. 엡스타인-바르 비루스 핵산 서열을 증폭시키고 증폭된 서열을 검측하기 위하여 프라이머(들)로서 제6항 내지 제8항의 핵산 서열이나 그것의 단편 중 적어도 하나를 사용하여 샘플내에 상기 엡스타인-바르 비루스 핵산 서열을 증폭시키고 검측하는 방법.
  24. 제20항 내지 제22항 중 어느 한 항의 방법을 실시하기 위한 실험 킷트.
  25. 제23항의 증폭 방법을 시하기 위한 시험 증폭 킷트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930003940A 1992-03-13 1993-03-13 엡스타인 바르 바이러스와 관련된 펩티드 및 핵산 서열 Expired - Lifetime KR100291247B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL92200721.6 1992-03-13
EP92200721 1992-03-13
EP92200721.6 1992-03-13

Publications (2)

Publication Number Publication Date
KR930019829A true KR930019829A (ko) 1993-10-19
KR100291247B1 KR100291247B1 (ko) 2001-06-01

Family

ID=8210477

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930003940A Expired - Lifetime KR100291247B1 (ko) 1992-03-13 1993-03-13 엡스타인 바르 바이러스와 관련된 펩티드 및 핵산 서열

Country Status (13)

Country Link
US (1) US5424398A (ko)
EP (2) EP0574048B1 (ko)
JP (3) JP4135996B2 (ko)
KR (1) KR100291247B1 (ko)
AT (2) ATE222291T1 (ko)
AU (1) AU666920B2 (ko)
CA (1) CA2092680C (ko)
DE (2) DE69332197T2 (ko)
DK (2) DK0574048T3 (ko)
ES (2) ES2184735T3 (ko)
FI (1) FI114802B (ko)
PT (1) PT574048E (ko)
ZA (1) ZA931797B (ko)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330966T2 (de) * 1993-07-23 2002-06-06 Wolf, Hans DNA-Sequenzen des Epstein-Barr Virus kodierend für ein diagnostisch relevantes Virus-Hüllprotein, durch PCR erhaltene Expressionsklone und Verwendung dieses rekombinanten Antigens in diagnostischen Tests
ATE231556T1 (de) * 1993-09-14 2003-02-15 Biomerieux Bv Diagnostische reagenzien zum nachweis von antikörper gegen ebv
US5834747A (en) * 1994-11-04 1998-11-10 Pixel Instruments Universal credit card apparatus and method
DE19526384C2 (de) * 1995-07-19 1997-07-10 Biotest Ag Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, sowie diese enthaltende Testkits zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern
US5813500A (en) * 1996-03-25 1998-09-29 Tenneco Automotive Inc. Anti-swish mechanism for a damper
FR2765688B1 (fr) * 1997-07-04 1999-09-10 Pasteur Institut Reactif de detection et de suivi des infections provoquees par le virus d'epstein-barr et ses applications
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US7105496B2 (en) 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
EP1022286A4 (en) * 1997-10-07 2003-04-09 Ono Pharmaceutical Co POLYPEPTIDES, FOR ENDING CODNA AND THEIR USE
AU757404B2 (en) * 1998-03-04 2003-02-20 Akzo Nobel N.V. Oligonucleotides for the amplification and detection of epstein barr virus (EBV) nucleic acid
US20030064917A1 (en) * 1998-07-23 2003-04-03 Crawford Susan E. Methods and compositions for inhibiting angiogenesis
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
US6965010B2 (en) * 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
US20030143647A1 (en) * 2001-09-24 2003-07-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diagnostic methods and reagents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2003226141A1 (en) * 2002-03-27 2003-10-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for treating cancer in humans
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US6886670B2 (en) * 2003-09-29 2005-05-03 Tenneco Automotive Operating Company Inc. Extra support land for valve disc
DE10307517A1 (de) * 2003-02-21 2004-09-02 Mikrogen Molekularbiologische Entwicklungs-Gmbh Von Kapsidantigenen des Epstein-Barr-Virus abgeleitete Peptide und ihre Verwendung
US6899207B2 (en) 2003-09-29 2005-05-31 Tenneco Automotive Operating Company Inc. Extra support area for valve disc
AU2005255019B2 (en) * 2004-06-12 2011-05-19 Oregon Health And Science University Compositions and methods for diagnosis and treatment of orthopoxviruses
US7278987B2 (en) * 2004-07-09 2007-10-09 Anthony Solazzo Ergonomic urological catheterization/irrigation tray
WO2007044033A2 (en) * 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
EP2311531A1 (en) 2005-12-01 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-viral griffithsin compounds, compositions, and methods of use
WO2007071448A2 (en) 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
US7868228B2 (en) 2006-01-31 2011-01-11 Monsanto Technology Llc Phosphopantetheinyl transferases from bacteria
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
WO2010011994A2 (en) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides and uses thereof
CN102186876B (zh) 2008-10-14 2014-06-11 孟山都技术公司 来自半片藻属的脂肪酸脱饱和酶的利用
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
SG10201505672TA (en) 2009-07-06 2015-09-29 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US20120213781A1 (en) 2011-02-11 2012-08-23 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP3348575A1 (en) 2011-08-16 2018-07-18 Emory University Jaml specific binding agents, antibodies, and uses related thereto
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2813849A1 (en) * 2013-06-10 2014-12-17 Charité-Universitätsmedizin Berlin (Charité) EBV-specific immune signature as diagnostic markers in Chronic Fatigue Syndrome (CFS)
CA2935123A1 (en) 2014-01-09 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-viral cnidarins
AU2016219434B2 (en) 2015-02-10 2020-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Griffithsin mutants
ES2876947T3 (es) 2015-02-13 2021-11-15 Univ Illinois Inhibición con péptidos de enfermedades o afecciones mediadas por CCR3
WO2016201503A1 (en) 2015-06-15 2016-12-22 Monash University Il-37 variants
US10703786B2 (en) 2015-10-30 2020-07-07 The University Of Melbourne Methods and compositions for improving glucose metabolism
CN108490177B (zh) * 2018-02-08 2020-12-29 深圳市新产业生物医学工程股份有限公司 鼻咽癌抗体检测试剂、其制备方法及鼻咽癌检测试剂盒
WO2021021774A1 (en) 2019-07-29 2021-02-04 The Board Of Trustees Of The University Of Illinois Composition and method for promoting wound healing
JP7751581B2 (ja) 2019-12-20 2025-10-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｉｌ－３７融合タンパク質及びその使用
AU2021385049A1 (en) 2020-11-18 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tyrosyl-lock peptides
EP4504766A1 (en) 2022-04-01 2025-02-12 The Board of Trustees of the University of Illinois Notch1 and notch4 decoys and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291636A1 (en) * 1983-11-07 1988-11-23 The Wistar Institute Immune response to viruses induced by anti-idiotype antibodies
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
IE873041L (en) * 1987-11-11 1989-05-11 Ailbe Brennan Viral antigens, diagnostic assay therefor and vaccines¹containing them
AU6164890A (en) * 1989-08-10 1991-03-11 Northwestern University Method of identifying herpesviruses and oligonucleotides for use therein
WO1991008224A1 (en) * 1989-11-24 1991-06-13 The Council Of The Queensland Institute Of Medical Research Im peptides
ZA9010188B (en) * 1989-12-20 1991-08-28 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma
JPH04310861A (ja) * 1991-04-09 1992-11-02 Kazuo Yanagi 抗ｅｂｎａ抗体の測定方法および抗ｅｂｎａ抗体測定キット

Also Published As

Publication number Publication date
ES2298325T3 (es) 2008-05-16
FI114802B (fi) 2004-12-31
DE69334191D1 (de) 2008-01-17
JP2004261183A (ja) 2004-09-24
PT574048E (pt) 2002-12-31
EP0574048A3 (ko) 1994-03-02
DE69332197T2 (de) 2003-04-17
FI931109A0 (fi) 1993-03-12
EP0574048B1 (en) 2002-08-14
ZA931797B (en) 1993-09-30
JP4135996B2 (ja) 2008-08-20
DE69334191T2 (de) 2008-11-27
EP1225226B1 (en) 2007-12-05
ATE222291T1 (de) 2002-08-15
CA2092680A1 (en) 1993-09-14
DK1225226T3 (da) 2008-04-14
JPH0690787A (ja) 1994-04-05
CA2092680C (en) 2006-08-08
JP4365440B2 (ja) 2009-11-18
FI931109L (fi) 1993-09-14
EP0574048A2 (en) 1993-12-15
DE69332197D1 (de) 2002-09-19
JP4106041B2 (ja) 2008-06-25
ES2184735T3 (es) 2003-04-16
KR100291247B1 (ko) 2001-06-01
ATE380243T1 (de) 2007-12-15
DK0574048T3 (da) 2002-12-16
EP1225226A1 (en) 2002-07-24
AU3515293A (en) 1993-09-16
US5424398A (en) 1995-06-13
JP2008261851A (ja) 2008-10-30
AU666920B2 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
KR930019829A (ko) 엡스타인 바르 비루스(Epstein Barr Virus)와 관련된 펩티드 및 핵산 서열
Cunningham et al. The UL13 virion protein of herpes simplex virus type 1 is phosphorylated by a novel virus-induced protein kinase
US20090098528A1 (en) Method for determining early HCV seroconversion
Christensen et al. The nucleolar protein, B-36, contains a glycine and dimethylarginine-rich sequence conserved in several other nuclear RNA-binding proteins
Xiong et al. Identification by immunoprecipitation of cauliflower mosaic virus in vitro major translation product with a specific serum against viroplasm protein
Ackermann et al. Application of antibody to synthetic peptides for characterization of the intact and truncated alpha 22 protein specified by herpes simplex virus 1 and the R325 alpha 22-deletion mutant
US5229491A (en) Peptides immunochemically reactive with antibodies directed against hepatitis non-a, non-b virus
EP0307149B1 (en) Solid phase immunoassay for an antibody and biological constructions for use therein
KR100378942B1 (ko) 엡스타인-바비루스(ebv)에대한항체의검출용진단시약
Liu et al. Identification of two new polypeptides encoded by mRNA5 of the coronavirus infectious bronchitis virus
WO1994005700A3 (en) Methods and reagents to detect and characterize norwalk and related viruses
Joab et al. Mapping of the gene coding for Epstein-Barr virus-determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector
CA2178057C (en) Epstein-barr virus peptides and antibodies against these peptides
Marsden et al. The herpes simplex virus type 1 UL8 protein influences the intracellular localization of the UL52 but not the ICP8 or POL replication proteins in virus-infected cells
KR20130088845A (ko) 인간 사이토메갈로 바이러스 감염의 검출 방법
US5620843A (en) Non-A non-B sequences
Cross et al. Generation and properties of the glycoprotein E-related 32K/34K/35K and 55K/57K polypeptides encoded by herpes simplex virus type 1
Friefeld et al. The 140-kDa adenovirus DNA polymerase is recognized by antibodies to Escherichia coli-synthesized determinants predicted from an open reading frame on the adenovirus genome.
KR960001122A (ko) 재조합 단일사슬 Fv 항체 절편과 B형 간염 바이러스 표면 항원의 면역정제를 위한 그 용도
EP0525910A1 (en) Non-A, non-B peptide
EP0607425A1 (en) Epstein-barr virus peptides and antibodies against these peptides
Stewart et al. Enhanced expression of the Epstein–Barr virus latent membrane protein by a recombinant vaccinia virus
Montano et al. Monoclonal antibody analysis of simian virus 40 small t-antigen expression in infected and transformed cells
EP0536838A2 (en) Non-A, non-B peptides
Münch et al. The core histone-binding region of the murine cytomegalovirus 89K immediate early protein

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930313

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19980219

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19930313

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19991125

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20000731

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19991125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20000901

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20000731

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20001211

Appeal identifier: 2000101002022

Request date: 20000901

PB0901 Examination by re-examination before a trial

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20000901

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20000425

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20001211

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20001128

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20010309

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20010310

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20040220

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20050223

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20060223

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20070228

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20080219

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20090220

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20100302

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20110224

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20120223

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20130226

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20130226

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20131022

Termination category: Expiration of duration